--- title: "DC 6329 - Hemorrhagic fevers, including dengue, yellow fever, and others" diagnostic_code: "6329" body_system: "Infectious Diseases, Immune Disorders and Nutritional Deficiencies" cfr_section: "§ 4.88b" canonical: "https://veteranai.co/va-rating-schedule/infectious-and-immune/6329-hemorrhagic-fevers-including-dengue-yellow-fever-and-others" source: "https://www.ecfr.gov/current/title-38/section-4.88b" updated: "2026-07-21T20:30:51.724943Z" --- # DC 6329 - Hemorrhagic fevers, including dengue, yellow fever, and others Rated under § 4.88b. Body system: Infectious Diseases, Immune Disorders and Nutritional Deficiencies. General Rating Formula for Infectious Diseases ## Rating criteria | Rating | Criteria | | --- | --- | | 100% | For active disease | | 100% | As active disease | | 100% | As active disease | | 100% | As active disease | | 100% | As active disease | | 100% | Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia | | 60% | With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor | | 40% | With stomatitis, diarrhea, and symmetrical dermatitis | | 20% | With stomatitis, or achlorhydria, or diarrhea | | 10% | Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability | | 100% | With congestive heart failure, anasarca, or Wernicke-Korsakoff syndrome | | 60% | With cardiomegaly, or; with peripheral neuropathy with footdrop or atrophy of thigh or calf muscles | | 30% | With peripheral neuropathy with absent knee or ankle jerks and loss of sensation, or; with symptoms such as weakness, fatigue, anorexia, dizziness, heaviness and stiffness of legs, headache or sleep disturbance | | 100% | Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia | | 60% | With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor | | 40% | With stomatitis, diarrhea, and symmetrical dermatitis | | 20% | With stomatitis, or achlorhydria, or diarrhea | | 10% | Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability | | 100% | As active disease | | 0% | As acute or asymptomatic chronic disease | | 100% | Not to be combined with ratings under DC 7809 Acute, with frequent exacerbations, producing severe impairment of health | | 60% | Exacerbations lasting a week or more, 2 or 3 times per year | | 10% | Exacerbations once or twice a year or symptomatic during the past 2 years | | 100% | AIDS with recurrent opportunistic infections (see Note 3) or with secondary diseases afflicting multiple body systems; HIV-related illness with debility and progressive weight loss | | 60% | Refractory constitutional symptoms, diarrhea, and pathological weight loss; or minimum rating following development of AIDS-related opportunistic infection or neoplasm | | 30% | Recurrent constitutional symptoms, intermittent diarrhea, and use of approved medication(s); or minimum rating with T4 cell count less than 200 | | 10% | Following development of HIV-related constitutional symptoms; T4 cell count between 200 and 500; use of approved medication(s); or with evidence of depression or memory loss with employment limitations | | 0% | Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count | | 100% | Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care | | 60% | Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level; or which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year | | 40% | Which are nearly constant and restrict routine daily activities from 50 to 75 percent of the pre-illness level; or which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year | | 20% | Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level; or which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total duration per year | | 10% | Which wax and wane but result in periods of incapacitation of at least one but less than two weeks total duration per year; or symptoms controlled by continuous medication | ## Notes - Note: Rate under the appropriate body system any residual disability of infection, which includes, but is not limited to, conditions of the central nervous system, liver, or kidney. # Hemorrhagic Fevers (VA Diagnostic Code 6329) *Includes dengue, yellow fever, and other hemorrhagic fevers* **Body System:** Infectious Diseases, Immune Disorders and Nutritional Deficiencies **Regulation:** 38 CFR § 4.88b — General Rating Formula for Infectious Diseases --- ## What This Condition Is Diagnostic Code 6329 covers hemorrhagic fevers, a group of infectious diseases that includes dengue, yellow fever, and others. Under the VA rating schedule, this condition is evaluated using the **General Rating Formula for Infectious Diseases**. Because an infection can leave lasting effects on the body, the VA also accounts for any residual disability that remains after the active infection. --- ## Available Rating Levels The VA assigns a disability rating for hemorrhagic fevers based primarily on whether the disease is active, along with the severity and frequency of symptoms. The rating levels associated with this code include: | Rating | What It Reflects | |--------|------------------| | **100%** | For active disease. | | **0%** | As acute or asymptomatic chronic disease. | Ratings are also available for symptom patterns described in the general formula, such as symptoms that: - **100%** — Are nearly constant and so severe as to restrict routine daily activities almost completely, and which may occasionally preclude self-care. - **60%** — Are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level; **or** which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year. - **40%** — Are nearly constant and restrict routine daily activities from 50 to 75 percent of the pre-illness level; **or** which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year. - **20%** — Are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level; **or** which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total duration per year. - **10%** — Wax and wane but result in periods of incapacitation of at least one but less than two weeks total duration per year; **or** symptoms controlled by continuous medication. --- ## What the VA Looks For When rating hemorrhagic fevers, the VA considers: - **Whether the disease is active.** Active disease is rated at 100%, while acute or asymptomatic chronic disease is rated at 0%. - **How constant the symptoms are.** The formula distinguishes between symptoms that are nearly constant and those that wax and wane. - **How much daily life is affected.** The VA measures the degree to which routine daily activities are restricted compared to the pre-illness level. - **Periods of incapacitation.** The total duration of incapacitation over a year is a key factor in the wax-and-wane categories. - **Use of continuous medication.** Symptoms controlled by continuous medication are recognized at the 10% level. ### Residual Effects **Note:** Any residual disability of the infection is rated under the appropriate body system. This includes, but is not limited to, conditions of the central nervous system, liver, or kidney. --- *This overview is drawn directly from the VA rating schedule for Diagnostic Code 6329 under 38 CFR § 4.88b. It is provided for general information and does not predict any individual rating outcome.* Source: https://www.ecfr.gov/current/title-38/section-4.88b